| Literature DB >> 33553201 |
Kelly Budge1, Sergio Dellepiane1, Samuel Mon-Wei Yu1, Paolo Cravedi1.
Abstract
Currently available treatments of diabetic kidney disease (DKD) remain limited despite improved understanding of DKD pathophysiology. The complement system is a central part of innate immunity, but its dysregulated activation is detrimental and results in systemic diseases with overt inflammation. Growing evidence suggests complement activation in DKD. With existent drugs and clinical success of treating other kidney diseases, complement inhibition has emerged as a potential novel therapy to halt the progression of DKD. This article will review DKD, the complement system's role in diabetic and non-diabetic disease, and the potential benefits of complement targeting therapies especially for DKD patients.Entities:
Keywords: C3a; C5a; MAC; complement; diabetes; diabetic kidney disease; glomerulosclerosis
Year: 2021 PMID: 33553201 PMCID: PMC7858668 DOI: 10.3389/fmed.2020.599236
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X